Evidence map›Paper›PMID 29330726›Full record

ArticleDigestive diseases and sciences2018

Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients.

Enass A Abdel-Hameed, Susan D Rouster, Ceejay L Boyce, Xiang Zhang, Jacek Biesiada, Mario Medvedovic, Kenneth E Sherman

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Enass A Abdel-HameedUniversity of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH, 45267-0595, USA.
Susan D RousterUniversity of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH, 45267-0595, USA.
Ceejay L BoyceUniversity of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH, 45267-0595, USA.
Xiang ZhangDepartment of Environmental Health, University of Cincinnati, Cincinnati, OH, 45267, USA.
Jacek BiesiadaDepartment of Environmental Health, University of Cincinnati, Cincinnati, OH, 45267, USA.
Mario MedvedovicDepartment of Environmental Health, University of Cincinnati, Cincinnati, OH, 45267, USA.
Kenneth E ShermanUniversity of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH, 45267-0595, USA. Kenneth.Sherman@uc.edu.ORCID 0000-0002-0560-0019
Sabin Vaccine Institute · USUniversity of Cincinnati · US

Funding

REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY RESEARCHP30ES006096 · NIEHS · UNIVERSITY OF CINCINNATI · PI PINNEY, SUSAN MENGEL · 1992 to 2022
$35.4M
Merck Sharp and Dohme MISPNIEHS NIH HHS P30-ES006096
6 · The paper itself

Abstract

BACKGROUND AND

aimsThe prevalence of naturally occurring HCV-NS5A resistance-associated substitutions (RAS) to DAA drugs might affect the response to treatment in HCV/HIV coinfected subjects. There are limited data on the frequency of HCV-NS5A naturally occurring drug-RAS at baseline in HCV/HIV coinfected patients when ultra-deep sequencing methodologies are applied.

methodsHCV-NS5A-RAS were evaluated among 25 subjects in each group. Patients were matched by age, gender, and hepatic fibrosis stage category to control for selection bias.

resultsWithin subtype 1a, RAS were observed in 28% of HCV monoinfected and 48% of HCV/HIV coinfected subjects. More patients in the HCV/HIV coinfected group had clinically relevant mutations to DAA directed at NS5A.

conclusionWhile the clinical significance of this observation may be limited in highly drug adherent populations, some HCV/HIV coinfected persons may be at greater risk of viral resistance if suboptimal dosing occurs.

Indexed as

AdultAntiviral AgentsBenzofuransCase-Control StudiesCoinfectionDrug CombinationsDrug Resistance, ViralFemaleHepacivirusHepatitis CHigh-Throughput Nucleotide SequencingHIV InfectionsHumansImidazolesMaleMiddle AgedAntiviral AgentsBenzofuransDrug Combinationselbasvir-grazoprevir drug combinationImidazolesNS-5 protein, hepatitis C virusQuinoxalinesRNA-Dependent RNA PolymeraseViral Nonstructural ProteinsDirectly acting antiviral therapyHCV/HIV coinfectionNS5A drug resistance-associated variants/polymorphism

Identifiers

PMID29330726
OpenAlexW2783190442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.